Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Warren

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
RMD Open|November 13, 2024
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trialJohanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, et al.
Rheumatology (Oxford, England)|September 29, 2023
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseasesIngrid Jyssum, Johanna E Gehin, Joseph Sexton, et al.
The Journal of Organic Chemistry|August 1, 2023
Diastereoselective and Scalable Synthesis of 6-(<i>S</i>)-HydroxycannabidivarinHannah V Stone, Frederick J Topping, Alberte X Veiga, et al.
Zootaxa|April 12, 2023
Earthworms (Clitellata, Megadrili) of the world: an updated checklist of valid species and families, with notes on their distributionMete Misirlioğlu, John Warren Reynolds, Mirjana Stojanović, et al.
Gut|February 26, 2025
Serological screening for coeliac disease in an adult general population: the HUNT studyIna Lervåg Andersen, Polina Lukina, Ole T Dyrli, et al.
The Lancet. Rheumatology|February 25, 2024
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trialsMarthe Kirkesæther Brun, Johanna E Gehin, Kristin Hammersbøen Bjørlykke, et al.
Journal of Internal Medicine|April 12, 2022
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trialMarthe Kirkesaether Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, et al.
Elife|May 23, 2019
Mechanism of completion of peptidyltransferase centre assembly in eukaryotesVasileios Kargas, Pablo Castro-Hartmann, Norberto Escudero-Urquijo, et al.
Journal of Internal Medicine|February 27, 2023
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseasesMarthe Kirkesaether Brun, Kristin Hammersbøen Bjørlykke, Marte K Viken, et al.
The Journal of Urology|March 11, 2005
A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitisRobert Mayer, Kathleen Joy Propert, Kenneth M Peters, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
RMD Open|November 13, 2024
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trialJohanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, et al.
Rheumatology (Oxford, England)|September 29, 2023
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseasesIngrid Jyssum, Johanna E Gehin, Joseph Sexton, et al.
The Journal of Organic Chemistry|August 1, 2023
Diastereoselective and Scalable Synthesis of 6-(<i>S</i>)-HydroxycannabidivarinHannah V Stone, Frederick J Topping, Alberte X Veiga, et al.
Zootaxa|April 12, 2023
Earthworms (Clitellata, Megadrili) of the world: an updated checklist of valid species and families, with notes on their distributionMete Misirlioğlu, John Warren Reynolds, Mirjana Stojanović, et al.
Gut|February 26, 2025
Serological screening for coeliac disease in an adult general population: the HUNT studyIna Lervåg Andersen, Polina Lukina, Ole T Dyrli, et al.
The Lancet. Rheumatology|February 25, 2024
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trialsMarthe Kirkesæther Brun, Johanna E Gehin, Kristin Hammersbøen Bjørlykke, et al.
Journal of Internal Medicine|April 12, 2022
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trialMarthe Kirkesaether Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, et al.
Elife|May 23, 2019
Mechanism of completion of peptidyltransferase centre assembly in eukaryotesVasileios Kargas, Pablo Castro-Hartmann, Norberto Escudero-Urquijo, et al.
Journal of Internal Medicine|February 27, 2023
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseasesMarthe Kirkesaether Brun, Kristin Hammersbøen Bjørlykke, Marte K Viken, et al.
The Journal of Urology|March 11, 2005
A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitisRobert Mayer, Kathleen Joy Propert, Kenneth M Peters, et al.
Pageof 11